Analysis and functional consequences of increased Fab-sialylation of intravenous immunoglobulin (IVIG) after lectin fractionation - Wikidata - awgldk - TriplyDB

Analysis and functional consequences of increased Fab-sialylation of intravenous immunoglobulin (IVIG) after lectin fractionation

Analysis and functional consequences of increased Fab-sialylation of intravenous immunoglobulin (IVIG) after lectin fractionation

http://www.wikidata.org/entity/Q28728886

about

Induction of Regulatory T Cells by Intravenous Immunoglobulin: A Bridge between Adaptive and Innate Immunity Intravenous immunoglobulin and Alzheimer's disease: what now?Immune recruitment or suppression by glycan engineering of endogenous and therapeutic antibodies B cells and CD22 are dispensable for the immediate antiinflammatory activity of intravenous immunoglobulins in vivo.Controlled tetra-Fc sialylation of IVIg results in a drug candidate with consistent enhanced anti-inflammatory activity.IVIG regulates the survival of human but not mouse neutrophils.Increased sialylation of anti-Thomsen-Friedenreich antigen (CD176) antibodies in patients with gastric cancer: a diagnostic and prognostic potential Protection in antibody- and T cell-mediated autoimmune diseases by antiinflammatory IgG Fcs requires type II FcRs.Anti-aβ oligomer IgG and surface sialic acid in intravenous immunoglobulin: measurement and correlation with clinical outcomes in Alzheimer's disease treatment.Production of α2,6-sialylated IgG1 in CHO cells Role of muscarinic-3 receptor antibody in systemic sclerosis: correlation with disease duration and effects of IVIG.Sialylated immunoglobulin G can neutralize influenza virus infection through receptor mimicry Fractionation of Fab glycosylated immunoglobulin G with concanavalin A chromatography unveils new structural properties of the molecule Hidden IgG Antibodies to the Tumor-Associated Thomsen-Friedenreich Antigen in Gastric Cancer Patients: Lectin Reactivity, Avidity, and Clinical Relevance.Intravenous immunoglobulin-induced IL-33 is insufficient to mediate basophil expansion in autoimmune patients The carbohydrate switch between pathogenic and immunosuppressive antigen-specific antibodies.Mechanisms and potential therapeutic targets in allergic inflammation: recent insights.B-cell modulation of dendritic-cell function: signals from the far side.Should development of Alzheimer's disease-specific intravenous immunoglobulin be considered?Immunomodulation by IVIg and the Role of Fc-Gamma Receptors: Classic Mechanisms of Action after all?Differences in Anti-Inflammatory Actions of Intravenous Immunoglobulin between Mice and Men: More than Meets the Eye.IVIG-mediated effector functions in autoimmune and inflammatory diseases.The Emerging Importance of IgG Fab Glycosylation in Immunity.Clinical Use and Therapeutic Potential of IVIG/SCIG, Plasma-Derived IgA or IgM, and Other Alternative Immunoglobulin Preparations.The potential of intravenous immunoglobulins for cancer therapy: a road that is worth taking?Rapid and improved characterization of therapeutic antibodies and antibody related products using IdeS digestion and subunit analysis.Biological roles of glycans.Modulators of IgG penetration through the blood-brain barrier: Implications for Alzheimer's disease immunotherapy.Will sialylation change intravenous immunoglobulin therapy in the future?Human Fc receptor-like 5 binds intact IgG via mechanisms distinct from those of Fc receptors.Therapeutic effect of IVIG on inflammatory arthritis in mice is dependent on the Fc portion and independent of sialylation or basophils.Autoantibodies targeting tumor-associated antigens in metastatic cancer: Sialylated IgGs as candidate anti-inflammatory antibodies.Highly parallel characterization of IgG Fc binding interactions.The protective effect of immunoglobulin in murine tuberculosis is dependent on IgG glycosylation.Sialylation may be dispensable for reciprocal modulation of helper T cells by intravenous immunoglobulin.Antibody blood-brain barrier efflux is modulated by glycan modification.Differential antibody glycosylation in autoimmunity: sweet biomarker or modulator of disease activity?Adaptive antibody diversification through N-linked glycosylation of the immunoglobulin variable region.Microheterogeneity of Recombinant Antibodies: Analytics and Functional Impact.Variable Domain N-Linked Glycans Acquired During Antigen-Specific Immune Responses Can Contribute to Immunoglobulin G Antibody Stability.

P2860

Q26781290-8DD2BB42-F60D-4BC1-9599-FAF3880C873B Q27000371-56FD83C6-8E42-41F7-980C-F305B9C66CD7 Q28069362-68AA6BF1-9D8B-435B-BCD0-0782F2A882B3 Q33403107-88E44A6A-6100-411C-8C9F-9C530AF55810 Q33420853-E1A59661-C416-44C3-9FAB-0F2E84554FB2 Q33683531-74300970-DF43-4A7E-AAAF-11C066B779AF Q34208137-449B7723-B204-4E5A-8B19-5ED38056C3D6 Q35590264-93320E33-1CAC-479C-AAAE-A83607D73B52 Q35590968-7E81BE64-33C1-4CB9-B583-F585BC56DD2E Q36213335-13B235A1-0A83-4263-8E65-52455BE997F2 Q37071790-9E1E693C-9502-48D1-93E9-F6351757C6AA Q37085836-51CC2B71-CB01-41D7-806D-AE9FCCECF011 Q37327690-3D619FE8-5633-4D9F-96AC-2884D9603C69 Q37683571-3369EC2C-8AB6-4F96-9BB7-BD467F4153AA Q37732919-67C3843D-1798-4295-9738-D07E9EC32255 Q38117686-6D5DCDD4-8507-4BB6-9D0C-868D0907423B Q38161574-D303AF9F-49CF-47C9-ACBF-ECD5EA0F798A Q38168787-5ADB39AE-AEE3-4B27-87ED-C7468E683164 Q38283308-34A08D57-1B79-447D-821A-A5522FC755E4 Q38344833-9BCA5393-011C-40B0-9FC6-76E10EF3F2F9 Q38478867-71420C1B-3EF7-4441-8C94-E3E5D7B5537D Q38699812-4CD3426E-7FF1-4FEF-BE94-A71B1F7658DB Q38724772-334E56C9-35E7-4353-BF8D-D86EA9C16DD6 Q38820288-927B11FB-66F9-4D80-941A-4256E9EA8C7B Q38824186-2E943732-908D-489F-8170-484187C8A101 Q38828582-F00D5455-052E-4736-815C-48EE08F3EA36 Q38936714-F65B0168-255F-4BD5-B65A-A17638C80D24 Q39062945-10FF0657-5FBB-4099-85A1-558292F519CF Q39067348-FF048A83-66DF-4851-8D72-D04FA0D92C2D Q39160831-38E5B447-430F-4179-B5F7-A5388199E0D3 Q39729881-2E4BE088-5C4F-46A1-B237-1E77728BF3F1 Q41762205-B914028D-D9EB-4AE3-AAC7-6A4CB9211376 Q42909129-5B9DA483-85D5-48FB-A814-C648B202ADEE Q44900805-FB5C9D46-5212-466F-B52B-F36D1D5987A9 Q45422267-7DAAE3A3-D867-419B-BBEA-8046271C0573 Q46348633-1981F7C2-0A0B-4187-815E-9936FCE2F102 Q47804590-EC1E3A1F-5CC9-4027-B45C-972CAD035CD4 Q50063710-C8FD928D-F210-4BB3-9DA0-9D7AC94E59BE Q50237001-46E0AB29-E00E-4909-B795-9D4D1D4BA69E Q55091658-34097BD0-0FD1-41D8-9DE1-38971998B14C

P2860

Analysis and functional consequences of increased Fab-sialylation of intravenous immunoglobulin (IVIG) after lectin fractionation

http://www.wikidata.org/entity/Q28728886

description

2012 թուականին հրատարակուած գիտական յօդուած

@hyw

2012 թվականին հրատարակված գիտական հոդված

@hy

article publié dans la revue scientifique PLoS ONE

@fr

artículu científicu espublizáu en 2012

@ast

im Januar 2012 veröffentlichter wissenschaftlicher Artikel

@de

scientific article (publication date: 2012)

@en

vedecký článok (publikovaný 2012)

@sk

vědecký článek publikovaný v roce 2012

@cs

wetenschappelijk artikel (gepubliceerd in 2012)

@nl

наукова стаття, опублікована у 2012

@uk

name

Analysis and functional conseq ...... IG) after lectin fractionation

@ast

Analysis and functional conseq ...... IG) after lectin fractionation

@en

Analysis and functional conseq ...... IG) after lectin fractionation

@nl

type

label

Analysis and functional conseq ...... IG) after lectin fractionation

@ast

Analysis and functional conseq ...... IG) after lectin fractionation

@en

Analysis and functional conseq ...... IG) after lectin fractionation

@nl

prefLabel

Analysis and functional conseq ...... IG) after lectin fractionation

@ast

Analysis and functional conseq ...... IG) after lectin fractionation

@en

Analysis and functional conseq ...... IG) after lectin fractionation

@nl

P1433

Q28728886-2B6AF93D-B2AF-4DA0-9609-256B425F20A2

P1476

Q28728886-B9A0C5F0-DF91-4C4B-B564-13A7813C0F59

P2093

Q28728886-19D8C79F-3708-4E73-9B18-1EA15A14D223

Q28728886-59C7A807-B9D6-4108-8074-8EBD580AA0F3

Q28728886-5DFC35BF-958B-4AF7-B118-D1B64325049F

Q28728886-A7E585DB-6468-45B3-AC1A-F9137B447E5D

Q28728886-ADE00526-4732-4467-B5ED-0EF44FE84136

Q28728886-D22B498D-626A-4E8A-8C3B-FF2142E0E306

P2860

Q28728886-024D2B76-A074-44CC-A7ED-4B6DA0A0E77B

Q28728886-0532F264-71B3-4FA0-91D0-67D0343125D1

Q28728886-093C3AE6-B8C7-4082-A75A-B2806F412CE5

Q28728886-097F96DB-064E-48F4-9C42-AD5141130440

Q28728886-0BDA2767-17DD-420A-A409-E775DFF52CC3

Q28728886-1024ADBE-4728-46CA-9451-B0307E9955A1

Q28728886-1428CD1D-12B0-4DC4-ACFF-B1C58192C04B

Q28728886-19A588D0-40CF-4404-8AA8-7546095D41A1

Q28728886-1A9150BD-5148-4301-8583-7FB111F7FB35

Q28728886-2177149F-5F9F-4729-B836-5DF31DE0436A

P304

Q28728886-9CD6B447-22D1-4C56-B5B1-487D2C7B94A5

P31

Q28728886-4BD28A98-697A-4808-A142-6647C156EFEC

P3181

Q28728886-78529453-E50B-4236-B516-433BE1B7AE77

P356

Q28728886-9DC06092-805E-451E-A51F-60242CC5F875

P407

Q28728886-ADAD4494-6D51-4851-83DF-3A1EA99C2254

P433

Q28728886-C8928E54-F896-4BF4-826E-602C003A1CC8

P478

Q28728886-1F94F889-2348-42FA-920F-D6F222CFAC66

P50

Q28728886-9877D827-1D3C-44D8-B4AC-840D0A8FDE52

P577

Q28728886-1CBF68CD-6811-4347-AFF7-60C3A698C0E5

P5875

Q28728886-9343CA68-2A70-4729-BA1C-ADCD72D4D26E

P698

Q28728886-2908D7E3-5CEE-4249-828F-F3260D52622A

P932

Q28728886-276C803A-9E16-4388-9B7C-684DAF5E917F

P3181

P356

JOURNAL.PONE.0037243

P1433

P1476

Analysis and functional conseq ...... IG) after lectin fractionation

@en

P2093

Adrian W Zuercher

http://www.w3.org/2001/XMLSchema#string

Andreas Hofmann

http://www.w3.org/2001/XMLSchema#string

David J Boerema

http://www.w3.org/2001/XMLSchema#string

Monika Rüegsegger

http://www.w3.org/2001/XMLSchema#string

Sandra Wymann

http://www.w3.org/2001/XMLSchema#string

Sylvia Miescher

http://www.w3.org/2001/XMLSchema#string

P2860

Activation of natural regulatory T cells by IgG Fc-derived peptide "Tregitopes"

A close look at human IgG sialylation and subclass distribution after lectin fractionation

Anti-inflammatory actions of intravenous immunoglobulin

Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc.

The antiinflammatory IgG.

Intravenous immunoglobulins induce potentially synergistic immunomodulations in autoimmune disorders.

Mechanisms of action of intravenous immunoglobulins.

The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders.

Enrichment of sialylated IgG by lectin fractionation does not enhance the efficacy of immunoglobulin G in a murine model of immune thrombocytopenia.

Sialylation-independent mechanism involved in the amelioration of murine immune thrombocytopenia using intravenous gammaglobulin.

P304

e37243

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2220962

http://www.w3.org/2001/XMLSchema#string

P356

10.1371/JOURNAL.PONE.0037243

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-06-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

225276608

http://www.w3.org/2001/XMLSchema#string

P698

22675478

http://www.w3.org/2001/XMLSchema#string

P932

3366990

http://www.w3.org/2001/XMLSchema#string